Internal Medicine, Gastroenterology · Omaha, NE
NPI
1619099629
Since 2007
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
8901 Indian Hills Dr, Suite 200
Omaha, NE, 68114
Phone (402) 397-7057
Groups this clinician bills Medicare through
Medicare paid, 2024
$833K
45,063 services
Medicare patients, 2024
723
Average age 73
Drug cost, 2024
$1.4M
1,392 prescriptions
Company payments, 2025
$887
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John J Cannella III was code J3380 (injection, vedolizumab, intravenous, 1 mg), 30,900 times for 66 patients. In total John J Cannella III billed 45,063 services in 60 codes, and Medicare paid $833K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-12-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3380 Injection, vedolizumab, intravenous, 1 mg | Office | 30,900 | 66 | $17.43 | $539K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 5,380 | 52 | $24.65 | $133K |
| 45385 Colonoscopy - Lesion Removal | Facility | 136 | 136 | $188.47 | $26K |
| 99213 Office E&M - Established | Office | 127 | 101 | $55.76 | $7,081 |
| 96365 Intravenous Infusion, Hydration | Office | 103 | 69 | $44.28 | $4,561 |
| 96413 Chemotherapy Administration | Office | 92 | 65 | $90.10 | $8,289 |
| 45380 Lower GI Endoscopy - Other | Facility | 90 | 90 | $103.05 | $9,275 |
| 43239 Upper GI Endoscopy | Facility | 78 | 78 | $75.21 | $5,866 |
| 43235 Upper GI Endoscopy | Facility | 73 | 73 | $63.74 | $4,653 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 63 | 63 | $162.20 | $10K |
| 99214 Office E&M - Established | Office | 55 | 44 | $78.86 | $4,337 |
| 99222 Hospital E&M - Initial | Facility | 46 | 46 | $94.60 | $4,351 |
| 96415 Chemotherapy Administration | Office | 42 | 28 | $19.11 | $803 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 31 | 31 | $159.39 | $4,941 |
| 36415 Venipuncture Blood Collection | Office | 26 | 22 | $8.65 | $225 |
By year: 2022 $379K for 15,054 services; 2023 $499K for 22,580 services; 2024 $833K for 45,063 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 26 | 22 | $8.65 | $225 |
Medicare prescription drug claims, 2024
In 2024, the drug John J Cannella III prescribed most often to Medicare patients was Peg 3350-Electrolyte (Sodium Chloride/Nahco3/Kcl/Peg), with 308 prescriptions and refills. In total John J Cannella III wrote 1,392 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg | 308 | 308 | 300 | $6,238 |
| Pantoprazole Sodium Generic | 233 | 484 | 60 | $2,551 |
| Omeprazole Generic | 90 | 227 | 30 | $1,344 |
| Dicyclomine Hcl Generic | 60 | 74 | 18 | $912 |
| Mercaptopurine Generic | 53 | 79 | Under 11 | $5,794 |
| Ursodiol Generic | 45 | 77 | Under 11 | $6,299 |
| Mesalamine Generic | 41 | 80 | 11 | $16K |
| Colestipol Hcl Generic | 35 | 51 | 13 | $2,155 |
| Stelara Ustekinumab | 35 | 43 | Under 11 | $913K |
| Sucralfate Generic | 31 | 56 | Under 11 | $1,890 |
| Linzess Linaclotide | 29 | 41 | Under 11 | $21K |
| Prednisone Generic | 25 | 39 | Under 11 | $342 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 25 | 25 | 25 | $1,609 |
| Amitriptyline Hcl Generic | 25 | 33 | Under 11 | $210 |
| Azathioprine Generic | 24 | 34 | Under 11 | $515 |
Brand drugs: 286 claims; generic drugs: 1,106 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John J Cannella III $887 ($887 in general payments such as food, travel and fees) from 12 companies. The largest payer was Abbvie Inc. with $270.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 20 | $270 |
| Gilead Sciences, Inc. GILD | 10 | $224 |
| Madrigal Pharmaceuticals MDGL | 5 | $98.7 |
| Janssen Biotech, Inc. JNJ | 3 | $75.25 |
| Phathom Pharmaceuticals, Inc. PHAT | 6 | $46.63 |
| Genzyme Corporation SNY | 2 | $44.1 |
| Intercept Pharmaceuticals, Inc. | 2 | $36.71 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 1 | $21.96 |
| Ardelyx, Inc. ARDX | 1 | $19.25 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $16.72 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.